Safety Concern With Fingolimod to Ocrelizumab Switch in MS Safety Concern With Fingolimod to Ocrelizumab Switch in MS

A new study has suggested that some patients who make this switch may experience"double immunosuppression" – very low levels of both T and B cells, and therefore be at increased risk for infection.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news